Cyclacel Pharmaceuticals logo
Cyclacel Pharmaceuticals CYCCP

Annual report 2025
added 03-30-2026

report update icon

Cyclacel Pharmaceuticals Cash Flow 2011-2026 | CYCCP

Annual Cash Flow Cyclacel Pharmaceuticals

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Operating Cash Flow

-4.77 M -7.99 M -16.1 M -20.8 M -18.5 M -7.93 M -9.45 M -6.7 M -7.48 M - - - - - -

Depreciation & Amortization

5 K 6 K 31 K 32 K 43 K 20 K 20 K 29 M 32 M 100 K 200 K 200 K 70 K 60 K 241 K

Accounts Payables

617 K 4.6 M 3.54 M 2.56 M 2.12 M 514 K 890 K 2.72 M 1.56 M 2.5 M 1.94 M 2.79 M 2.54 M 2.26 M 1.76 M

Total Inventories

1.38 M - - - - - - - - - - - - - -

All numbers in USD currency

Quarterly Cash Flow Cyclacel Pharmaceuticals

2025-Q3 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Operating Cash Flow

- -3.25 M - - - -483 K - - -6.86 M - -15.7 M -8.69 M -6.78 M - -14 M -7.78 M -3.57 M - -6.78 M -4.65 M -2.81 M - -8.33 M -6.32 M -3.68 M - -4.66 M -3.94 M -2.14 M - -5.26 M -4.01 M - - - - - - - - - - - - - - - - - - - - - - - - -

Depreciation & Amortization

- - - - - 2 K - - 8 K - 24 K 17 K 9 K - 36 K 26 K 9 K - 16 K 10 K 5 K - 15 K 10 K 6 K - 22 K 15 K 7 K - 25 K 17 K 9 K - 109 K 75 K 42 K - 157 K 102 K 52 K - 115 K 46 K 23 K - 58 K 36 K 26 K - 45 K 30 K 15 K - 250 K 172 K 86 K

Accounts Payables

468 K 114 K 4.6 M 4.13 M 4.74 M 5.2 M 3.54 M 2.17 M 2.51 M 2.56 M 983 K 2.2 M 2.85 M 2.12 M 1.52 M 1.2 M 871 K 514 K 514 K 514 K 514 K 890 K 890 K 890 K 890 K 2.72 M 2.72 M 2.72 M 2.72 M 1.56 M 1.56 M 1.56 M 1.56 M 2.5 M 2.5 M 2.5 M 2.5 M 1.94 M 1.94 M 1.94 M 1.94 M 2.79 M 2.79 M 2.79 M 2.79 M 2.54 M 2.54 M 2.54 M 2.54 M 2.26 M 2.26 M 2.26 M 2.26 M 1.72 M 1.72 M 1.76 M 1.76 M

Accounts Receivables

725 K - - - - - - - - - - - - - - - - - - - - - - - - - - 66 K 600 K - - 89 K 879 K 10 K - - 10 K - - - - - - - - - - - - - - 45 K - 116 K - - -

Total Inventories

1.37 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Cash Flow Statement is one of the three key financial reports of the company Cyclacel Pharmaceuticals, reflecting the actual cash inflows and outflows over a certain period. Unlike the income statement, which shows revenues and expenses on an accrual basis, the cash flow statement focuses on real cash flows — how much cash actually came into the company and how much was spent.

Main Sections of the Cash Flow Statement
  • Operating Activities
    This section reflects cash flows related to the company’s core operations: receipts from sales of goods and services, payments to suppliers, employee salaries, taxes, and other operating expenses. Positive cash flow from operating activities indicates the viability of the business and its ability to generate cash.
  • Investing Activities
    Shows cash movements related to the purchase and sale of long-term assets such as real estate, equipment, and investments in other companies. Negative cash flow here often indicates investments in growth, which can be a positive sign.
  • Financing Activities
    Reflects the inflow and outflow of cash related to raising and repaying capital: issuing shares, loans, dividend payments, and loan repayments. This section shows how the company finances its activities and distributes profits.

The cash flow statement is important for investors because it allows them to assess the company’s real liquidity, showing whether it has enough cash to cover current obligations and investments — this is critical for financial stability. Additionally, it helps analyze the quality of earnings, since profits reported in the income statement can be "paper" profits and may not reflect actual cash inflows; the cash flow statement reveals this difference. The presence of free cash is also crucial for evaluating the company’s ability to finance growth and pay dividends, which is important for investors. Attention should also be paid to prolonged negative cash flows from operating activities, as this may serve as a warning sign of potential problems with the core business.

Cash flow statements of other stocks in the Biotechnology sector

Issuer Price % 24h Market Cap Country
FSD Pharma FSD Pharma
HUGE
- 5743.5 % $ 69.7 M canadaCanada
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
Coherus BioSciences Coherus BioSciences
CHRS
$ 1.57 -3.68 % $ 184 M usaUSA
Happiness Biotech Group Limited Happiness Biotech Group Limited
HAPP
- 1.35 % $ 17.8 M chinaChina
Amphastar Pharmaceuticals Amphastar Pharmaceuticals
AMPH
$ 16.87 -2.49 % $ 789 M usaUSA
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
I-Mab I-Mab
IMAB
- - $ 866 M chinaChina
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
Genfit SA Genfit SA
GNFT
- 2.54 % $ 160 B franceFrance
AstraZeneca PLC AstraZeneca PLC
AZN
- - $ 96.9 B britainBritain
Arcturus Therapeutics Holdings Arcturus Therapeutics Holdings
ARCT
$ 7.47 -4.6 % $ 205 M israelIsrael
Athira Pharma Athira Pharma
ATHA
- - $ 269 M usaUSA
BiondVax Pharmaceuticals Ltd. BiondVax Pharmaceuticals Ltd.
BVXV
- 0.74 % $ 768 M israelIsrael
Eton Pharmaceuticals Eton Pharmaceuticals
ETON
$ 30.26 1.0 % $ 814 M usaUSA
Galera Therapeutics Galera Therapeutics
GRTX
- -32.59 % $ 7.61 M usaUSA
Exelixis Exelixis
EXEL
$ 50.13 -1.9 % $ 13.6 B usaUSA
Fortress Biotech Fortress Biotech
FBIO
$ 2.41 4.78 % $ 67.2 M usaUSA
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
Forte Biosciences Forte Biosciences
FBRX
$ 23.11 -3.55 % $ 299 M usaUSA
AbCellera Biologics AbCellera Biologics
ABCL
$ 4.09 -7.05 % $ 1.22 B canadaCanada
Autolus Therapeutics plc Autolus Therapeutics plc
AUTL
$ 1.63 2.52 % $ 434 M britainBritain
BioNTech SE BioNTech SE
BNTX
$ 89.55 -2.65 % $ 21.6 B germanyGermany
Checkmate Pharmaceuticals Checkmate Pharmaceuticals
CMPI
- - $ 231 M usaUSA
Galectin Therapeutics Galectin Therapeutics
GALT
$ 2.17 -7.66 % $ 139 M usaUSA
Celyad Oncology SA Celyad Oncology SA
CYAD
- - $ 12.5 M belgiumBelgium
Berkeley Lights Berkeley Lights
BLI
- -7.31 % $ 87 M usaUSA
Generation Bio Co. Generation Bio Co.
GBIO
- - $ 344 M usaUSA
IMV IMV
IMV
- - $ 13.1 M canadaCanada
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
- - $ 7.46 M israelIsrael
Gilead Sciences Gilead Sciences
GILD
$ 129.58 -1.88 % $ 161 B usaUSA
Advaxis Advaxis
ADXS
- -9.65 % $ 45.9 M usaUSA
Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd.
CANF
$ 3.36 -3.72 % $ 5.53 M israelIsrael
Aeterna Zentaris Aeterna Zentaris
AEZS
- 5.93 % $ 314 M canadaCanada
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
CureVac N.V. CureVac N.V.
CVAC
- - $ 867 M germanyGermany
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
- - $ 26.5 M usaUSA
AIkido Pharma AIkido Pharma
AIKI
- 1.93 % $ 17.4 M usaUSA
Enlivex Therapeutics Ltd. Enlivex Therapeutics Ltd.
ENLV
$ 0.72 -1.58 % $ 32.9 M israelIsrael
Esperion Therapeutics Esperion Therapeutics
ESPR
$ 3.12 - $ 649 M usaUSA
Aptose Biosciences Aptose Biosciences
APTO
- -45.71 % $ 1.2 M canadaCanada
Genmab A/S Genmab A/S
GMAB
$ 26.54 -1.34 % $ 1.72 B danmarkDanmark
Aptinyx Aptinyx
APTX
- -39.0 % $ 4.57 M usaUSA
Akouos Akouos
AKUS
- 0.23 % $ 488 M usaUSA
Albireo Pharma Albireo Pharma
ALBO
- -0.23 % $ 916 M usaUSA
AlloVir AlloVir
ALVR
- 4.14 % $ 49.1 M usaUSA
Allakos Allakos
ALLK
- - $ 28.6 M usaUSA